HCPLive Network

Hyponatremia Clinical Update, July 15, 2011

Seizures and Hyponatremia Related to Ethcathinone and Methylone Poisoning
In a recent issue of the Journal of Medical Toxicology, researchers from the Université Laval in Quebec, Canada, reported on a case of ethcathinone and methylone poisoning with severe clinical toxicity. The combination of ethcathinone and methylone is a form of MDMA (ecstasy) that is legal in some countries. According to the authors, to their knowledge, this is the first case reported in the medical toxicology literature.

According to the study, a 22-year-old woman was brought to the emergency department following several episodes of tonicoclonic seizures a few hours after ingesting “legal ecstasy.”

“The patient needed intubation for recurrent seizures, and she was found to have severe hyponatremia (120 mmol/L) that was corrected with hypertonic saline. The patient’s mental status improved rapidly, and she was extubated the day following her admission. However, she developed prolonged rhabdomyolysis (CK 34.537 U/L) that required a six-day hospitalization,” the authors wrote.

The researchers argue that the seizures and the hyponatremia experienced by the patient may be explained by the MDMA-like characteristics of methylone that may induce inappropriate secretion of antidiuretic hormone mediated via the serotonin system.

“The combination of methylone and ethcatinone (both acting like serotonin reuptake inhibitors) might have contributed to neurologic manifestations compatible with serotonin toxicity, although our patient never had autonomic instability. Our patient had a prolonged period of rhabdomyolysis which may also be explained by excessive serotonin activity resulting in an increased motor hyperactivity,” the authors wrote.
They go on to note that the public has to be aware of this growing health problem, and that clinicians must report future cases of toxicity related to the use of cathinone synthetic derivatives in order to increase knowledge of these substances.


Management of Hyponatremia and Volume Contraction
Hyponatremia, the most common electrolyte imbalance seen in patients with aneurysmal subarachnoid hemorrhage, occurrs in one-third to one-half of patients. Hyponatremia may be caused by cerebral salt wasting and by the syndrome of inappropriate secretion of antidiuretic hormone or a combination of both.

Because limited data are available describing hyponatremia treatment in subarachnoid hemorrhage patients, researchers at the Mayo Clinic performed a Medline search for English-language manuscripts describing original research in the treatment for hyponatremia in patients with aneurysmal subarachnoid hemorrhage. In an article published in a recent issue of Neurocritical Care, the authors identified seven appropriate articles, three testing fludrocortisone, two hydrocortisone, and one each for hypertonic saline and 5% albumin.

“Data quality for treatment efficacy and safety were moderate for corticosteroid studies and low or very low for hypertonic saline and 5% albumin. Available data, although limited, support early treatment with corticosteroids to limit hyponatremia, with fludrocortisone causing fewer side effects,” the authors wrote in the study abstract.

Sources
Seizures and Hyponatremia Related to Ethcathinone and Methylone Poisoning
[Journal of Medical Toxicology]

Management of Hyponatremia and Volume Contraction [Neurocritical Care]



Further Reading
A new study finds narrow health networks can help reduce healthcare costs without impacting the quality of care patients receive.
Movantik (naloxegol), an oral peripherally acting mu-opioid receptor antagonist, has been approved by the FDA for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
Paul Wicks, PhD, discusses the surge in Internet-savvy patients at the 2014 Joint ACTRIMS-ECTRIMS Meeting in Boston.
Men with male pattern baldness may face a higher risk of developing an aggressive type of prostate cancer than men with no balding, according to a study published online Sept. 15 in the Journal of Clinical Oncology.
Adding chest radiation to chemotherapy allows some people with small-cell lung cancer to live longer and cuts recurrence rates by nearly 50%, European researchers report. The research was published online Sept. 14 in The Lancet to coincide with presentation at the annual meeting of the American Society for Radiation Oncology, held from Sept. 14 to 18 in San Francisco.
As with many rare diseases, the treatment options for patients with familial hypercholesterolemias are few and far between. In this segment, the panelists discuss several viable options for treating this condition.
The US Department of Health and Human Services is sending nearly $300 million to community health centers in an effort to boost access to comprehensive primary care.
More Reading